Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 w...

Source: Arthritis Research and Therapy - October 11, 2023 Category: Rheumatology Authors: Michele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, Alen Zabotti, Roberta Ramonda, Maria Sole Chimenti, Lorenzo Dagna, Nicoletta Luciano, Anna Piccinelli, Ivan Giovannini, Giovanni Striani, Nicola Boffini, Gilda Sandri, Niccol ò Possemato Tags: Research Source Type: research